東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Asthma = targeted biological therapies /

Pelaia, Girolamo.

FindBook

Google Book

Amazon

博客來

Asthma = targeted biological therapies /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Asthma/ by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
其他題名:	targeted biological therapies /
作者:	Pelaia, Girolamo.
其他作者:	Vatrella, Alessandro.
出版者:	Cham :Springer International Publishing : : 2017.,
面頁冊數:	vi, 99 p. :ill., digital ;24 cm.
內容註:	Introduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.
Contained By:	Springer eBooks
標題:	Asthma - Treatment. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-46007-9
ISBN:	9783319460079

Asthma = targeted biological therapies /
Pelaia, Girolamo.

Asthmatargeted biological therapies /[electronic resource] :by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli. - Cham :Springer International Publishing :2017. - vi, 99 p. :ill., digital ;24 cm.

Introduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.

This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.

ISBN: 9783319460079

Standard No.: 10.1007/978-3-319-46007-9doiSubjects--Topical Terms:

1363452
Asthma
--Treatment.

LC Class. No.: RC591

Dewey Class. No.: 616.23806

Asthma = targeted biological therapies /
LDR:02538nmm a2200313 a 4500 001 2088733
003 DE-He213
005 20161112033317.0
006 m d
007 cr nn 008maaau
008 171013s2017 gw s 0 eng d
020 $a 9783319460079 $q (electronic bk.)
020 $a 9783319460055 $q (paper)
024 7 $a 10.1007/978-3-319-46007-9 $2 doi
035 $a 978-3-319-46007-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC591
072 7 $a MJL $2 bicssc
072 7 $a MED079000 $2 bisacsh
082 0 4 $a 616.23806 $2 23
090 $a RC591 $b .P381 2017
100 1 $a Pelaia, Girolamo. $3 3218741
245 1 0 $a Asthma $h [electronic resource] : $b targeted biological therapies / $c by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a vi, 99 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.
520 $a This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.
650 0 $a Asthma $x Treatment. $3 1363452
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Pneumology/Respiratory System. $3 894348
650 2 4 $a Allergology. $3 894540
650 2 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a General Practice / Family Medicine. $3 893976
650 2 4 $a Pediatrics. $3 559143
700 1 $a Vatrella, Alessandro. $3 3218742
700 1 $a Maselli, Rosario. $3 3218743
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46007-9
950 $a Medicine (Springer-11650)